Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 42 out of 100. Tau biomarkers

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Background The authors sought to examine the impact of the K-variant of butyrylcholinesterase (BCHE-K) carrier status on age-at-diagnosis of Alzheimer disease (AD) in APOE4 carriers. Methods Patients aged 50-74 years with cerebrospinal fluid (CSF) biomarker-confirmed AD, were recruited to clinical trial (NCT03186989 since June 14, 2017). Baseline demographics, disease characteristics, and biomarkers were evaluated in 45 patients according to BCHE-K and APOE4 allelic status in this post-hoc study.

What this study adds

Evidence grade: Low

The record lists 33 participants. In a post-hoc analysis of 45 patients with biomarker-confirmed Alzheimer's disease, those carrying both APOE4 and the butyrylcholinesterase K variant were diagnosed about 6.4 years earlier on average. It is about genetic influences on age at diagnosis, not about treating, curing or preventing the disease.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Lane, R. M., Darreh-Shori, T., Junge, C., Li, D., Yang, Q., Edwards, A. L., et al. (2024). Onset of Alzheimer disease in apolipoprotein ɛ4 carriers is earlier in butyrylcholinesterase K variant carriers. BMC neurology. https://doi.org/10.1186/s12883-024-03611-5

Vancouver

Lane RM, Darreh-Shori T, Junge C, Li D, Yang Q, Edwards AL, et al. Onset of Alzheimer disease in apolipoprotein ɛ4 carriers is earlier in butyrylcholinesterase K variant carriers. BMC neurology. 2024. doi:10.1186/s12883-024-03611-5. PMID: 38594621.

BibTeX

@article{lane2024-38594621,
  author  = {Lane, R. M. and Darreh-Shori, T. and Junge, C. and Li, D. and Yang, Q. and Edwards, A. L. and Graham, D. L. and Moore, K. and others},
  title   = {{Onset of Alzheimer disease in apolipoprotein ɛ4 carriers is earlier in butyrylcholinesterase K variant carriers}},
  journal = {BMC neurology},
  year    = {2024},
  doi     = {10.1186/s12883-024-03611-5},
  pmid    = {38594621},
  url     = {https://doi.org/10.1186/s12883-024-03611-5}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

In a post-hoc analysis of 45 patients with biomarker-confirmed Alzheimer's disease, those carrying both APOE4 and the butyrylcholinesterase K variant were diagnosed about 6.4 years earlier on average. It is about genetic influences on age at diagnosis, not about treating, curing or preventing the disease.

Study details

How this study scored 42/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 1 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 1 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 2 of 7; Citations per year 1 of 5; Impact for its field and year 2 of 6; Cited by studies here 0 of 6; Still being cited 1 of 4; Senior author's track record 2 of 4; Institution's track record 1 of 3; Multicenter collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 42 of 100.42 of 100 points earned58 not earned

Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (BMC neurology)
Journal's citation record 1 / 4 BMC Neurology: journal h-index 122 (OpenAlex, 2026-10-29)
Study design 0 / 12 Design recorded as “post-hoc analysis”, which our rubric does not rank (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2024 — within 3 year(s) of the newest study here
Sample size 1 / 4 33 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 2 / 7 Cited 6 times (OpenAlex, 2026-10-10)
Citations per year 1 / 5 1.5 citations a year over 4 year(s) since 2024
Impact for its field and year 2 / 6 Cited 1.4× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 1 / 4 Cited 6 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 2 / 4 Last-listed author Catherine Jane Mummery: h-index 41 (OpenAlex, whole career)
Institution's track record 1 / 3 Karolinska Institutet: institution h-index 1,477 (OpenAlex)
Multicenter collaboration 2 / 3 OpenAlex lists 4 institution(s) in 3 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 38594621)
Free to read 2 / 2 Free to read
Total 42 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 25.

Related studies in Tau biomarkers from nearby years

Also tagged “precursor”

1,337 studies in the library carry the topic tag “precursor”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,337 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Tau biomarkers

See all studies in Tau biomarkers →